Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells

We have recently demonstrated the safety and tolerability of a novel therapeutic regimen employing autologous blood cells chemically coupled with seven myelin peptides to induce antigen-specific tolerance in MS (ETIMS study). The aim of the current study was an extended safety analysis to assess the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis Jg. 21; H. 5; S. 651 - 655
Hauptverfasser: Peschl, Patrick, Reindl, Markus, Schanda, Kathrin, Sospedra, Mireia, Martin, Roland, Lutterotti, Andreas
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London, England SAGE Publications 01.04.2015
Sage Publications Ltd
Schlagworte:
Adult
Antibody Formation - drug effects
Autoantibodies - analysis
Autoantigens - adverse effects
Autoantigens - therapeutic use
Blood Cells - immunology
Dose-Response Relationship, Immunologic
Female
Humans
Immune Tolerance
Immunoglobulin G - analysis
Male
Middle Aged
Multiple Sclerosis - therapy
Myelin-Oligodendrocyte Glycoprotein - immunology
Vaccines - adverse effects
Vaccines - therapeutic use
myelin
antigen-coupled cell
Multiple sclerosis
antibody
tolerance
ISSN:1352-4585, 1477-0970, 1477-0970
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We have recently demonstrated the safety and tolerability of a novel therapeutic regimen employing autologous blood cells chemically coupled with seven myelin peptides to induce antigen-specific tolerance in MS (ETIMS study). The aim of the current study was an extended safety analysis to assess the effect of the ETIMS approach on antibodies to common autoantigens, the myelin peptides used and common recall antigens. None of the patients showed induction of autoantibody responses. One patient had a measurable myelin peptide-specific response at baseline, which was reduced after treatment. Total immunoglobulins and recall antibody responses showed no significant change.
Bibliographie:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:1352-4585
1477-0970
1477-0970
DOI:10.1177/1352458514549405